

National Medical Care Co. (Care)'s net profit reached SAR 42.6mn for Q3-22 (increasing 28.5% Y/Y, and 1.5% Q/Q). The results positively surprised our estimated SAR 38.4mn by SAR 4.2mn (at a deviation of 11%), and the market consensus of SAR 37.2mn (by 14.6%). The increase in net income, on a Y/Y and Q/Q basis, is attributed to an increase in patient volumes across all of their client bases (GOSI, insurance, and cash patients). Care cites GOSI as a high margin client, whom is now increasing business with the healthcare provider after a hiatus in GOSI's engagement with the firm. Atop the increased referrals from GOSI, GP margins also increased due to higher margin surgeries and admissions, and economies of scale from higher patient volumes. GP margins for Q3-22 then reached 34.7% (up 510bps Y/Y, and 390bps Q/Q), a historical record for Care. We revise our TP to **SAR 73.0/share**, at a "Neutral" recommendation.

- Care posted a net profit of SAR 42.6mn for Q3-22 (up 28.5% Y/Y, and 1.5% Q/Q), positively surprising our estimated SAR 38.4mn at a deviation of 11.0%, and the market consensus of SAR 37.2mn by 14.6%. The higher Q/Q results were attributed to a higher volume of patients coming from all client segments as well as an increase in higher GP margin business. Higher OPEX to revenues this quarter was an attrition to the bottom line, which still managed to record the highest net income reported by the firm since 2016. These factors punctuated to an EPS of SAR 0.95. The deviation from our estimates came as a result of the influx of patients seen by Care in Q3, and the margins the patients presented.
- The revenues reached by Care this quarter at SAR 238.3mn, came at an 11.8% Y/Y increase (and up 10.1% Q/Q from SAR 216.5mn), and above our expectations of SAR 209.8mn by 13.6%. The higher volume of patient inflows stemmed from their insurance client segment, as well as cash and contracts, and increased referrals from GOSI- a client that, with the MoH, makes the bulk of Care's client segments.
- Gross profits stood at SAR 82.7mn (up 31.1% Y/Y, and 23.8% Q/Q), deviating from our estimates as a result of the surprise in the volume of high margin business seen this quarter by Care from surgeries and admissions, and likely from the increase in GOSI referred patients. In turn, Care was able to successfully report its highest GP margins to date at 34.7% (up 510bps Y/Y and 390bps Q/Q, and above our estimated 30.1%).
- Care's operating income for the quarter stood at 49.1mn (increasing on a Y/Y and Q/Q basis by 22.2% and 30.0% respectively) and above our estimates of SAR 40.6mn by 20.9%. With higher provisions for expected credit losses, as well as SG&A costs, Care's OPEX expanded to 33.6mn, to make up 14.1% of revenues (up from 10.9% of revenues in Q3-21, and 9.6% in the previous quarter).

**AJC view and valuation:** Care posted a favorable set of result for Q3-22 with top line growth, and record margins to punctuate at a positively surprising net profit. As previously reported; with the limited expansion plans in Care's pipeline, the firm must focus on utilization rates and margins as it did so successfully this quarter. We anticipate that Care will be able to maintain its financial performances going forward, while facing a step cost in margins by the time the firm's third Riyadh based hospital becomes operational. Among the risks we are monitoring is the firm's high exposure to its government client base, a specification which previously resulted in uncertain outlooks as a result of a momentary withdrawal from GOSI's engagement with the firm. Besides its geographic competition, among the chief downside risks specific to Care is its sub-par receivables collections management; Care's receivables to revenues on a TTM basis stands at an astronomical 98.9% of revenues (not accounting for provisions on credit loss). The average among its peers stand 59.1% of TTM revenues. Should their collection management improve, this could significantly free up cash flows to the firm- Until then, we remain "Neutral" on the stock, while raising our TP to **SAR 73.0/share**.

SARmn	Q3-21	Q2-22	Q3-22	Change Y/Y	Change Q/Q	Deviation from AJC Estimates
Revenue	213.1	216.5	238.3	11.8%	10.1%	13.6%
Gross Profit	63.1	66.8	82.7	31.1%	23.8%	31.1%
<i>Gross Margin</i>	<i>29.6%</i>	<i>30.9%</i>	<i>34.7%</i>	-	-	-
EBIT	39.8	46.0	49.1	23.3%	6.8%	20.9%
<b>Net Profit</b>	<b>33.2</b>	<b>42.0</b>	<b>42.6</b>	<b>28.5%</b>	<b>1.5%</b>	<b>11.0%</b>
EPS	0.74	0.94	0.95	-	-	-

Source: Company Reports, AlJazira Capital

Recommendation	Neutral
Target Price (SAR)	73.0
Upside / (Downside)*	4.3%

Source: Tadawul \*prices as of 27th of November 2022

**Key Financials**

SARmn (unless specified)	FY20	FY21	FY22E	FY23E
Revenue	809.0	845.4	906.5	915.5
Growth %	14.2%	4.5%	7.2%	1.0%
Net Income	97.3	136.4	158.5	157.2
Growth %	21.3%	40.2%	16.3%	-0.8%
EPS	2.17	3.04	3.53	3.51

Source: Company reports, Aljazira Capital

**Key Ratios**


	FY20	FY21	FY22E	FY23E
Gross Margin	27.7%	29.2%	31.8%	31.7%
Net Margin	12.0%	16.1%	17.5%	17.2%
P/E (x)	28.9	23.0	19.8	20.0
P/B (x)	2.7	2.8	2.6	2.4
EV/EBITDA (x)	14.9	14.1	13.3	12.6

Source: Company reports, Aljazira Capital

**Key Market Data**

Market Cap (bn)	3.14bn
YTD %	11.0%
52 Week (High)/(Low)	84.60/50.70
Shares Outstanding (mn)	44.85

Source: Company reports, Aljazira Capital

**Price Performance**

Source: Company reports, Aljazira Capital

Equity Analyst  
 Ibrahim Elaiwat  
 +966 11 225 6115  
 i.elaiwat@aljaziracapital.com.sa



RESEARCH DIVISION

Head of Sell-Side Research - AGM  
Jassim Al-Jubran  
+966 11 2256248  
j.aljabran@aljaziracapital.com.sa

RESEARCH DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

## Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia. Tel: 011 2256000 - Fax: 011 2256068